Patents by Inventor Jeffrey A. Hubbell

Jeffrey A. Hubbell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Protein-binding peptide isolated from placenta growth factor
    Patent number: 9879062
    Abstract: Embodiments of the invention are described, including materials and methods for making molecules and materials that have a specific binding domain of a PlGF2. Embodiments include, for instance, medicaments, biomaterials, biomolecules, molecular fusions, and vaccines.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: January 30, 2018
    Assignee: Ecole Polytechnique Federale De Lausanne
    Inventors: Jeffrey A. Hubbell, Mikael Martino, Priscilla S. Maithili Briquez
  • Compositions for generating immune tolerance by targeting erythrocytes
    Patent number: 9878048
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: January 30, 2018
    Assignee: Ecole Polytechnique Federale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Erythrocyte-binding therapeutics
    Patent number: 9850296
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: December 26, 2017
    Assignee: Ecole Polytechnique Federale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Stéphane Kontos, Karen Y. Dane
  • Compositions for inducing antigen-specific tolerance
    Patent number: 9814780
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: November 14, 2017
    Assignee: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • GLYCOTARGETING THERAPEUTICS
    Publication number: 20170296636
    Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.
    Type: Application
    Filed: September 19, 2015
    Publication date: October 19, 2017
    Inventors: Jeffrey A. Hubbell, David Scott Wilson
  • CONFORMAL COATING OF CELLS FOR IMMUNOISOLATION
    Publication number: 20170216489
    Abstract: Hydrodynamic methods for conformally coating non-uniform size cells and cell clusters for implantation, thus preventing immune rejection or inflammation or autoimmune destruction while preserving cell functionality. A method for conformally coating cells and cell clusters with hydrogels that are biocompatible, mechanically and chemically stable and porous, with an appropriate pore cut-off size. The methods of the invention are advantageously reproducible and result in a relatively high yield of coated versus non-coated cell clusters, without compromising cell functionality. Conformal coating devices configured to perform the methods of the invention, methods of optimally utilizing said devices and purifying the coated islets, and coated biomaterials made by said methods.
    Type: Application
    Filed: April 4, 2017
    Publication date: August 3, 2017
    Inventors: Jeffrey Hubbell, Alice Tomei
  • ERYTHROCYTE-BINDING THERAPEUTICS
    Publication number: 20170066825
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.
    Type: Application
    Filed: November 21, 2016
    Publication date: March 9, 2017
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • GLYCOTARGETING THERAPEUTICS
    Publication number: 20170007708
    Abstract: Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.
    Type: Application
    Filed: June 17, 2016
    Publication date: January 12, 2017
    Inventors: Jeffrey A. Hubbell, David Scott Wilson
  • Extracellular matrix heparin-binding domains
    Patent number: 9540428
    Abstract: Heparin binding peptides derived from a Tenascin (TNC) III1-5 domain or a fibrinogen ?15-66 domain have been found that bind certain cytokines with high affinity. Materials and methods for making compositions and devices using these peptides are disclosed.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: January 10, 2017
    Assignee: Ecole Polytechnique Federale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Mikael Martino, Laura De Laporte, Jeffrey J. Rice, Federico Tortelli
  • METHODS FOR REDUCING IMMUNE RESPONSES
    Publication number: 20160361431
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Application
    Filed: August 9, 2016
    Publication date: December 15, 2016
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Erythrocyte-binding therapeutics
    Patent number: 9517257
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: December 13, 2016
    Assignee: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
    Inventors: Jeffrey A. Hubbell, Stéphane Kontos, Karen Y. Dane
  • Erythrocyte-binding therapeutics
    Patent number: 9518087
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.
    Type: Grant
    Filed: August 9, 2011
    Date of Patent: December 13, 2016
    Assignee: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
    Inventors: Jeffrey A. Hubbell, Stéphane Kontos, Karen Y. Dane
  • COMPOSITIONS FOR GENERATING IMMUNE TOLERANCE BY TARGETING ERYTHROCYTES
    Publication number: 20160354453
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Application
    Filed: August 9, 2016
    Publication date: December 8, 2016
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • COMPOSITIONS FOR INDUCING ANTIGEN-SPECIFIC TOLERANCE
    Publication number: 20160354484
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Application
    Filed: August 9, 2016
    Publication date: December 8, 2016
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • METHODS FOR INDUCTION OF ANTIGEN-SPECIFIC IMMUNE TOLERANCE
    Publication number: 20160354454
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Application
    Filed: August 9, 2016
    Publication date: December 8, 2016
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Triblock copolymers for cytoplasmic delivery of gene-based drugs
    Patent number: 9505867
    Abstract: The invention features a triblock copolymer including a hydrophilic block; a hydrophobic block; and a positively charged block capable of reversibly complexing a negatively charged molecule, e.g., a nucleic acid, wherein the hydrophobic block is disposed between the hydrophilic block and the positively charged block. Desirably, the triblock copolymer is capable of self-assembling into a supramolecular structure, such as a micelle or vesicle. The invention further features methods of delivering negatively charged molecules and methods of treating a disease or condition using the polymers of the invention.
    Type: Grant
    Filed: May 31, 2006
    Date of Patent: November 29, 2016
    Assignee: Ecole Polytechmique Fédérale De Lausanne
    Inventors: Tatiana Segura, Jeffrey A. Hubbell
  • BLOCK COPOLYMERS AND USES THEREOF
    Publication number: 20160256569
    Abstract: Block copolymers containing charged blocks or chemical moieties sensitive to oxidation or hydrolysis have been developed. We describe the use of such block copolymers in supramolecular structures, e.g., micelles or vesicles, and pharmaceutical compositions and in methods of preparing the supramolecular structures and pharmaceutical compositions. The invention is particularly useful for the delivery of pharmaceutical agents, e.g., nucleic acids, to cells.
    Type: Application
    Filed: February 5, 2016
    Publication date: September 8, 2016
    Inventors: James Brandon DIXON, Jeffrey A. HUBBELL, Conlin P. O'NEIL, Melody SWARTZ, Diana VELLUTO
  • GLYCOTARGETING THERAPEUTICS
    Publication number: 20160243248
    Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.
    Type: Application
    Filed: September 19, 2015
    Publication date: August 25, 2016
    Inventors: Jeffrey A. Hubbell, David Scott Wilson
  • COMPOUNDS AND FORMULATIONS FOR THE TREATMENT OF WOUNDS
    Publication number: 20160199343
    Abstract: The present invention relates to the treatment of wounds.
    Type: Application
    Filed: August 25, 2014
    Publication date: July 14, 2016
    Applicant: Nitto Denko Corporation
    Inventors: Geofrey De Visscher, Walter Eevers, Nicolas Schüwer, Takayuki Shigematsu, Mayu Takeiri, Jeffrey A. Hubbell, Federico Tortelli, De Titta Alexandre, Sandra Amiguet Vercher
  • HIGH ASPECT RATIO NANOFIBRIL MATERIALS
    Publication number: 20160177036
    Abstract: The present invention features linear and three-dimensional supramolecular materials self-assembled from block co-polymers comprising oligo(ethylene sulfide) (OES). The block copolymers assemble into fibrils, micelles, or matrices. The fibrillar materials are sensitive to oxidation, which leads to decreased OES block hydrophobicity and crystallinity, and increased water solubility of the polymer constituents. Molecular loading options, coupled with oxidative sensitivity, allow implantable or injectable fibrillar suspensions or cross-linked three-dimensional matrices to demonstrate significant biomedical potential, especially in the context of extracellular and intracellular molecular delivery and applications related to infection and disease.
    Type: Application
    Filed: July 24, 2014
    Publication date: June 23, 2016
    Inventors: Jeffrey A. Hubbell, Carrie E. Brubaker, Diana Velluto